Stay updated on Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.
Latest updates to the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page
- ChecktodayChange DetectedNew updates have been added, including a completion date of 2024-12-20 and an actual date of 2024-12-12, while previous entries such as 'Active, not recruiting' and several estimated dates have been removed.SummaryDifference0.7%
- Check7 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.3%
- Check15 days agoChange DetectedThe website has updated the contact details section for the study, replacing the previous information with new details and revising the certification dates.SummaryDifference3%
- Check22 days agoChange DetectedAbbVie has added new information regarding the IMGN853-0419 study, including a study director and helpful links, while ImmunoGen, Inc. has been removed from the list.SummaryDifference1%
- Check29 days agoChange DetectedThe website has added a 'Show less' feature while removing extensive details about participant groups, interventions, and various data fields available for download.SummaryDifference3%
- Check36 days agoChange DetectedThe website has been updated to version v2.12.2, adding new features for downloading study data in various formats and displaying detailed participant and study information, while removing the option to show less content.SummaryDifference3%
Stay in the know with updates to Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.